Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121939 · ClinicalTrials.gov registry record · Phase 2
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
A Phase 2 study of Neuroendocrine Carcinoma, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 9
- Study locations
NCT01121939: Completed Phase 2 study of Neuroendocrine Carcinoma, sponsored by SCRI Development Innovations.
NCT01121939 is a Phase 2 study of Neuroendocrine Carcinoma that has completed, run by SCRI Development Innovations. The registered enrollment target is 43 participants, below the 278-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (85% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01121939, a Phase 2 study of Neuroendocrine Carcinoma, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and pertuzumab treatment is of great interest. The primary endpoint of this trial will be response rate. Toxicity and progression-free survival will be obtained and evaluated.
Primary Outcome
The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Pertuzumab
- DRUG Sandostatin LAR® Depot
Study Locations (9)
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Hospital Cancer Institute - Orlando
Georgia
- Medical Oncology Associates of Augusta - Augusta
Kentucky
- Baptist Medical Center East - Louisville
Michigan
- Grand Rapids Oncology Program - Grand Rapids
Missouri
- Research Medical Center - Kansas City
New Jersey
- Hematology-Oncology Associates of Northern NJ - Morristown
Ohio
- Oncology Hematology Care, Inc - Cincinnati
Tennessee
- Tennessee Oncology Associates - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
What the finished NCT01121939 record still lists
NCT01121939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 278-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01121939 lists 9 locations in 8 states (Florida, Georgia, Kentucky).
Frequently Asked Questions
What is clinical trial NCT01121939 about?
NCT01121939 is a clinical study titled "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers". The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and pertuzumab treatment is of great interest. The prima...
What is the current status of trial NCT01121939?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-05. Estimated completion is 2015-08.
What conditions does trial NCT01121939 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT01121939?
The interventions under investigation include: Bevacizumab (DRUG), Pertuzumab (DRUG), Sandostatin LAR® Depot (DRUG).
Who is sponsoring clinical trial NCT01121939?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01121939 being conducted?
This trial has 9 study locations across Florida, Georgia, Kentucky, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01121939's enrollment target sits among peer trials
43 10th of 13 higher than 4 of 13 other Neuroendocrine Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia